PHAXIAM Therapeutics S.A. (PHXM.PA)

EUR 0.31

(-27.91%)

Total Liabilities Summary of PHAXIAM Therapeutics S.A.

  • PHAXIAM Therapeutics S.A.'s latest annual total liabilities in 2023 was 25.69 Million EUR , up 15.1% from previous year.
  • PHAXIAM Therapeutics S.A.'s latest quarterly total liabilities in 2024 Q2 was 23.66 Million EUR , up 192.38% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported annual total liabilities of 22.32 Million EUR in 2022, down -49.17% from previous year.
  • PHAXIAM Therapeutics S.A. reported annual total liabilities of 43.92 Million EUR in 2021, down -18.45% from previous year.
  • PHAXIAM Therapeutics S.A. reported quarterly total liabilities of 23.66 Million EUR for 2024 Q2, up 192.38% from previous quarter.
  • PHAXIAM Therapeutics S.A. reported quarterly total liabilities of 25.69 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of PHAXIAM Therapeutics S.A. (2023 - 2016)

Historical Annual Total Liabilities of PHAXIAM Therapeutics S.A. (2023 - 2016)

Year Total Liabilities Total Liabilities Growth
2023 25.69 Million EUR 15.1%
2022 22.32 Million EUR -49.17%
2021 43.92 Million EUR -18.45%
2020 53.86 Million EUR 63.29%
2019 32.98 Million EUR 48.33%
2018 22.23 Million EUR 60.66%
2017 13.84 Million EUR 48.38%
2016 9.32 Million EUR 0.0%

Peer Total Liabilities Comparison of PHAXIAM Therapeutics S.A.

Name Total Liabilities Total Liabilities Difference
Nicox S.A. 31.56 Million EUR 18.602%
European Medical Solutions 33.86 Million EUR 24.127%
FERMENTALG 19.39 Million EUR -32.462%
argenx SE 402.79 Million EUR 93.621%
BioSenic S.A. 32.26 Million EUR 20.36%
Celyad Oncology SA 9.97 Million EUR -157.517%
Hyloris Pharmaceuticals SA 8.61 Million EUR -198.363%
Onward Medical N.V. 25.69 Million EUR 0.012%
Oxurion NV 19.73 Million EUR -30.194%
Financière de Tubize SA 123.65 Million EUR 79.22%
UCB SA 6.56 Billion EUR 99.609%